Business
After years of contraction, investors see biotech reentering a growth cycle driven by scientific progress, asset quality and renewed conviction in oncology, obesity and neuroscience innovation.
FEATURED STORIES
With the biopharma industry performing better of late, analysts, executives and other industry watchers are “cautiously optimistic”—a term heard all over the streets of San Francisco at the J.P. Morgan Healthcare Conference earlier this month.
Attendance at the Biotech CEO Sisterhood’s annual photo of women leaders and allies in Union Square doubled this year. There’s still more work to do.
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
T-knife GmbH, based in Berlin, Germany, closed a €66 million (about $78.4 million, U.S.) Series A round.
Several polls have suggested that as much as half of the U.S. population is unlikely to get the vaccine for a variety of reasons, including not feeling it is safe.
With a $30 million investment, Versant Ventures launches Matterhorn Biosciences AG, a company developing T cell receptor therapies based on the recent discovery of MR1-restricted T (MRIT) cells that recognize and kill a wide range of tumors of various tissue origins.
Data security risks are growing as more and more clinical trials embrace telemedicine and other digital technologies.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 5, 2020.
Two years after AbbVie and Voyager Therapeutics first forged a collaboration to develop treatments for Alzheimer’s disease, the partnership has come to an end after AbbVie terminated the agreement.
Startup IgGenix, Inc. emerged from stealth mode with $10 million in Series A financing and a goal to advance the company’s novel antibody therapeutics platform for the treatment of food and non-food allergies, as well as other severe allergic conditions.
With billions of doses of COVID-19 vaccines expected to be available by year’s end, and a global population of 7.8 billion, public health officials are scrambling to deliver the vaccines in ways that are equitable and effective.
Russia’s minister of health, Mikhail Murashko, indicated that the country plans a nationwide program to vaccinate its population against COVID-19 starting in October.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 3, 2020.